Literature DB >> 29668927

Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.

Jason C Choi1, Wei Wu2,3, Elizabeth Phillips1, Robin Plevin4, Fusako Sera2, Shunichi Homma2, Howard J Worman2,3.   

Abstract

Mutations in the lamin A/C gene (LMNA) encoding the nuclear intermediate filament proteins lamins A and C cause a group of tissue-selective diseases, the most common of which is dilated cardiomyopathy (herein referred to as LMNA cardiomyopathy) with variable skeletal muscle involvement. We previously showed that cardiomyocyte-specific overexpression of dual specificity protein phosphatase 4 (DUSP4) is involved in the pathogenesis of LMNA cardiomyopathy. However, how mutations in LMNA activate Dusp4 expression and whether it is necessary for the development of LMNA cardiomyopathy are currently unknown. We now show that female LmnaH222P/H222P mice, a model for LMNA cardiomyopathy, have increased Dusp4 expression and hyperactivation of extracellular signal-regulated kinase (ERK) 1/2 with delayed kinetics relative to male mice, consistent with the sex-dependent delay in the onset and progression of disease. Mechanistically, we show that the H222P amino acid substitution in lamin A enhances its binding to ERK1/2 and increases sequestration at the nuclear envelope. Finally, we show that genetic deletion of Dusp4 has beneficial effects on heart function and prolongs survival in LmnaH222P/H222P mice. These results further establish Dusp4 as a key contributor to the pathogenesis of LMNA cardiomyopathy and a potential target for drug therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29668927      PMCID: PMC6005151          DOI: 10.1093/hmg/ddy134

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  78 in total

1.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

2.  Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging.

Authors:  Dale K Shumaker; Thomas Dechat; Alexander Kohlmaier; Stephen A Adam; Matthew R Bozovsky; Michael R Erdos; Maria Eriksson; Anne E Goldman; Satya Khuon; Francis S Collins; Thomas Jenuwein; Robert D Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-31       Impact factor: 11.205

3.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.

Authors:  Matthew R G Taylor; Pamela R Fain; Gianfranco Sinagra; Misi L Robinson; Alastair D Robertson; Elisa Carniel; Andrea Di Lenarda; Teresa J Bohlmeyer; Debra A Ferguson; Gary L Brodsky; Mark M Boucek; Jean Lascor; Andrew C Moss; Wai Lun P Li; Gary L Stetler; Francesco Muntoni; Michael R Bristow; Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  An early growth response protein (Egr) 1 cis-element is required for gonadotropin-releasing hormone-induced mitogen-activated protein kinase phosphatase 2 gene expression.

Authors:  T Zhang; M W Wolfe; M S Roberson
Journal:  J Biol Chem       Date:  2001-10-08       Impact factor: 5.157

6.  Inactivation of JNK activity by mitogen-activated protein kinase phosphatase-2 in EAhy926 endothelial cells is dependent upon agonist-specific JNK translocation to the nucleus.

Authors:  C J Robinson; C M Sloss; R Plevin
Journal:  Cell Signal       Date:  2001-01       Impact factor: 4.315

7.  The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade.

Authors:  J M Brondello; A Brunet; J Pouysségur; F R McKenzie
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

8.  ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene.

Authors:  Maria Chatzifrangkeskou; Caroline Le Dour; Wei Wu; John P Morrow; Leroy C Joseph; Maud Beuvin; Fusako Sera; Shunichi Homma; Nicolas Vignier; Nathalie Mougenot; Gisèle Bonne; Kenneth E Lipson; Howard J Worman; Antoine Muchir
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

9.  Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation.

Authors:  Jason C Choi; Wei Wu; Antoine Muchir; Shinichi Iwata; Shunichi Homma; Howard J Worman
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

10.  Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies.

Authors:  Takuro Arimura; Anne Helbling-Leclerc; Catherine Massart; Shaida Varnous; Florence Niel; Emmanuelle Lacène; Yves Fromes; Marcel Toussaint; Anne-Marie Mura; Dagmar I Keller; Helge Amthor; Richard Isnard; Marie Malissen; Ketty Schwartz; Gisèle Bonne
Journal:  Hum Mol Genet       Date:  2004-11-17       Impact factor: 6.150

View more
  3 in total

1.  A lamin A/C variant causing striated muscle disease provides insights into filament organization.

Authors:  Rafael Kronenberg-Tenga; Meltem Tatli; Matthias Eibauer; Wei Wu; Ji-Yeon Shin; Gisèle Bonne; Howard J Worman; Ohad Medalia
Journal:  J Cell Sci       Date:  2021-03-22       Impact factor: 5.285

Review 2.  Role of Lamin A/C Gene Mutations in the Signaling Defects Leading to Cardiomyopathies.

Authors:  Andrea Gerbino; Giuseppe Procino; Maria Svelto; Monica Carmosino
Journal:  Front Physiol       Date:  2018-09-25       Impact factor: 4.566

3.  Deficiency of emerin contributes differently to the pathogenesis of skeletal and cardiac muscles in LmnaH222P/H222P mutant mice.

Authors:  Eiji Wada; Megumi Kato; Kaori Yamashita; Hiroko Kokuba; Wen-Chen Liang; Gisèle Bonne; Yukiko K Hayashi
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.